Adial Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable and Other Operating Liabilities
Adial Pharmaceuticals, Inc. (ADIL) reported Increase (Decrease) in Accounts Payable and Other Operating Liabilities of $405.08 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities · last filed 2026-03-05
- Adial Pharmaceuticals, Inc. increase (decrease) in accounts payable and other operating liabilities for fiscal 2025 was $405.08K, a 175.93% increase from fiscal 2024.
- Adial Pharmaceuticals, Inc. increase (decrease) in accounts payable and other operating liabilities for fiscal 2024 was $146.81K.
- Adial Pharmaceuticals, Inc. increase (decrease) in accounts payable and other operating liabilities for fiscal 2023 was -$183.47K.
| Period end | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 12 month |
|---|---|
| 2025-12-31 | $405.08K 10-K · filed 2026-03-05 |
| 2024-12-31 | $146.81K 10-K · filed 2026-03-05 |
| 2023-12-31 | -$183.47K 10-K · filed 2025-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |